Tele: 561.316.3330

Breaking Medical Device Industry News

Friday, October 22, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeCritical Care Immunotherapy

Critical Care Immunotherapy

CytoSorbents Partners with InvoSurg and Surgical Partners

CytoSorbents is now aggressively expanding CytoSorb availability, marketing, and sales opportunities across the U.S. to help address the current and expected future waves of COVID-19 infection in the country.

CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense

CytoSorbents reports the HemoDefend-BGA filter is designed to enable "universal plasma", or plasma that can be administered to anyone regardless of blood type, and to improve the safety of whole blood transfusions, by the rapid and efficient removal of anti-A and anti-B antibodies from these two blood products.

CytoSorb, the Wuhan Coronavirus, and Cytokine Storm

In this publication, Huang, et al. describe the characteristics and clinical course of hospitalized patients infected with the Wuhan coronavirus who did, or did not, require treatment in the intensive care unit.

CytoSorb® Removal of Ticagrelor Intraoperatively Results in Projected Cost Savings of Approximately $5,000 in Each Patient Undergoing Emergency Cardiac Surgery

Dr. Eric Mortensen, MD, Ph.D., Chief Medical Officer of CytoSorbents, will present data from a new study on the cost-effectiveness of CytoSorb when used intraoperatively to remove ticagrelor in patients undergoing emergency open-heart surgery.  The presentation will occur at the 33rd Annual Meeting of the European Association for Cardio-Thoracic Surgery  (EACTS) in Lisbon, Portugal on Saturday, October 5, 2019. 

By using this website you agree to accept Medical Device News Magazine Privacy Policy